ARCHIVES OF THE TURKISH SOCIETY OF CARDIOLOGY

1Department of Pediatrics, Health Sciences University School of Medicine, Kayseri City Training and Research Hospital, Kayseri, Turkey 2Division of Pediatric Cardiology, Department of Pediatrics, Health Sciences University School of Medicine, Kayseri City Training and Research Hospital, Kayseri, Turkey 3Department of Medical Biochemistry, Health Sciences University School of Medicine, Kayseri City Training and Research Hospital, Kayseri, Turkey

[1]  A. Quisi,et al.  The relationship between galectin-3 and SYNTAX Score I in patients with non-ST-segment elevation myocardial infarction. , 2020, Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir.

[2]  A. E. van den Bosch,et al.  Prognostic value of galectin-3 in adults with congenital heart disease , 2017, Heart.

[3]  G. Limongelli,et al.  Pediatric Heart Failure: A Practical Guide to Diagnosis and Management. , 2017, Pediatrics and Neonatology.

[4]  K. Meyer.  Pulmonary fibrosis, part II: state-of-the-art patient management , 2017, Expert review of respiratory medicine.

[5]  M. Emdin,et al.  Inhibition of Galectin-3 Pathway Prevents Isoproterenol-Induced Left Ventricular Dysfunction and Fibrosis in Mice , 2016, Hypertension.

[6]  G. Hansmann,et al.  Galectin-3 and aldosterone as potential tandem biomarkers in pulmonary arterial hypertension , 2016, Heart.

[7]  E. Rimm,et al.  Galectin‐3 Is Elevated and Associated With Adverse Outcomes in Patients With Single‐Ventricle Fontan Circulation , 2016, Journal of the American Heart Association.

[8]  M. Sugimoto,et al.  Cardiac biomarkers in children with congenital heart disease , 2015, World Journal of Pediatrics.

[9]  R. Wachter,et al.  Galectin‐3 in patients with heart failure with preserved ejection fraction: results from the Aldo‐DHF trial , 2015, European journal of heart failure.

[10]  P. Traber,et al.  Therapy of Experimental NASH and Fibrosis with Galectin Inhibitors , 2013, PloS one.

[11]  Bertram Pitt,et al.  Genetic and Pharmacological Inhibition of Galectin-3 Prevents Cardiac Remodeling by Interfering With Myocardial Fibrogenesis , 2013, Circulation. Heart failure.

[12]  R. Gascoyne,et al.  Galectin-3 binds to CD45 on diffuse large B-cell lymphoma cells to regulate susceptibility to cell death. , 2012, Blood.

[13]  C. Delcayre,et al.  Aldosterone Inhibits Antifibrotic Factors in Mouse Hypertensive Heart , 2012, Hypertension.

[14]  D. J. Veldhuisen,et al.  Galectin‐3: a novel mediator of heart failure development and progression , 2009, European journal of heart failure.

[15]  S. Arsan,et al.  The incidence and follow-up of isolated ventricular septal defect in newborns by echocardiographic screening. , 2008, The Turkish journal of pediatrics.

[16]  V. Dudnyk,et al.  Instrumental assessment of myocardial function by doppler tissue imaging in children with congenital heart defects after surgical correction and its correlation with galectin-3 amount as biological marker of cardiac fibrosis. , 2019, Wiadomosci lekarskie.

[17]  R. D. de Boer,et al.  Galectin-3 in Heart Failure: An Update of the Last 3 Years. , 2018, Heart failure clinics.

[18]  M. Cantinotti,et al.  Incidence and natural history of neonatal isolated ventricular septal defects: Do we know everything? A 6‐year single‐center Italian experience follow‐up , 2018, Congenital heart disease.

[19]  J. Gaziano,et al.  Meta-Analysis of the Usefulness of Plasma Galectin-3 to Predict the Risk of Mortality in Patients With Heart Failure and in the General Population. , 2017, The American journal of cardiology.

[20]  O. Youssef,et al.  Galectin-3 in Children with Chronic Heart Failure with Normal and Reduced Ejection Fraction: Relationship to Disease Severity , 2016, Pediatric Cardiology.

[21]  N. Narin,et al.  Single-center results of the use of transcatheter closure for ventricular septal defects , 2015 .

[22]  F. Zannad,et al.  The impact of galectin-3 inhibition on aldosterone-induced cardiac and renal injuries. , 2015, JACC. Heart failure.